Total Payments
$431,360
2024 Payments
$60,897
Companies
38
Transactions
409
Medicare Patients
403
Medicare Billing
$59,955
Payment Breakdown by Category
Consulting$302,339 (70.1%)
Travel$72,633 (16.8%)
Other$39,427 (9.1%)
Research$9,220 (2.1%)
Food & Beverage$6,809 (1.6%)
Education$838.44 (0.2%)
Gifts$93.44 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $302,339 | 112 | 70.1% |
| Travel and Lodging | $72,633 | 114 | 16.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $25,474 | 10 | 5.9% |
| Unspecified | $9,220 | 18 | 2.1% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $7,133 | 2 | 1.7% |
| Honoraria | $6,820 | 3 | 1.6% |
| Food and Beverage | $6,809 | 146 | 1.6% |
| Education | $838.44 | 2 | 0.2% |
| Gift | $93.44 | 2 | 0.0% |
Payments by Type
General
$422,140
391 transactions
Research
$9,220
18 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $121,869 | 127 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $50,302 | 75 | $0 (2024) |
| NOVARTIS PHARMACEUTICALS CORPORATION | $38,785 | 33 | $0 (2023) |
| Bayer Healthcare Pharmaceuticals Inc. | $34,377 | 17 | $0 (2023) |
| EMD Serono, Inc. | $29,289 | 22 | $0 (2020) |
| SERVIER PHARMACEUTICALS LLC | $21,852 | 3 | $0 (2022) |
| Regeneron Pharmaceuticals, Inc. | $20,234 | 19 | $0 (2024) |
| Janssen Global Services, LLC | $14,992 | 5 | $0 (2022) |
| Teva Pharmaceuticals USA, Inc. | $11,400 | 2 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $8,862 | 20 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $60,897 | 45 | Merck Sharp & Dohme LLC ($25,518) |
| 2023 | $53,782 | 60 | Merck Sharp & Dohme LLC ($15,132) |
| 2022 | $49,757 | 30 | SERVIER PHARMACEUTICALS LLC ($21,852) |
| 2021 | $42,715 | 27 | Merck Sharp & Dohme Corporation ($14,500) |
| 2020 | $21,736 | 15 | Merck Sharp & Dohme Corporation ($6,850) |
| 2019 | $63,345 | 72 | Novartis Pharmaceuticals Corporation ($17,504) |
| 2018 | $86,559 | 90 | Merck Sharp & Dohme Corporation ($26,137) |
| 2017 | $52,568 | 70 | Merck Sharp & Dohme Corporation ($18,121) |
All Payment Transactions
409 individual payment records from CMS Open Payments — Page 1 of 17
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $2,880.00 | General |
| 12/06/2024 | ABBVIE INC. | — | — | Cash or cash equivalent | $1,350.00 | Research |
| Study: Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors | ||||||
| 12/05/2024 | Teva Pharmaceuticals USA, Inc. | — | Consulting Fee | Cash or cash equivalent | $5,700.00 | General |
| 12/05/2024 | Teva Pharmaceuticals USA, Inc. | — | Consulting Fee | Cash or cash equivalent | $5,700.00 | General |
| 11/15/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $64.17 | General |
| Category: ONCOLOGY | ||||||
| 11/15/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $32.66 | General |
| Category: ONCOLOGY | ||||||
| 11/15/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $11.38 | General |
| Category: ONCOLOGY | ||||||
| 11/15/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $11.38 | General |
| Category: ONCOLOGY | ||||||
| 11/14/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | — | In-kind items and services | $1,360.00 | Research |
| Study: A phase 1b,2, multicenter, open-label study of S-531011 as monotherapy and in combination with an immune checkpoint inhibitor in participants with locally advanced or metastatic solid tumors • Category: ONCOLOGY | ||||||
| 11/14/2024 | Genmab U.S., Inc. | — | Consulting Fee | Cash or cash equivalent | $675.00 | General |
| 11/08/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Consulting Fee | Cash or cash equivalent | $4,380.00 | General |
| Category: ONCOLOGY | ||||||
| 11/08/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Consulting Fee | Cash or cash equivalent | $2,920.00 | General |
| Category: ONCOLOGY | ||||||
| 11/08/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Consulting Fee | Cash or cash equivalent | $918.00 | General |
| Category: ONCOLOGY | ||||||
| 11/08/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Consulting Fee | Cash or cash equivalent | $730.00 | General |
| Category: ONCOLOGY | ||||||
| 11/04/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $4,270.00 | General |
| 11/04/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| 10/22/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $152.26 | General |
| Category: ONCOLOGY | ||||||
| 10/21/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $312.31 | General |
| Category: ONCOLOGY | ||||||
| 10/21/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $75.85 | General |
| Category: ONCOLOGY | ||||||
| 10/21/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $16.73 | General |
| Category: ONCOLOGY | ||||||
| 10/20/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $312.31 | General |
| Category: ONCOLOGY | ||||||
| 10/20/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $152.26 | General |
| Category: ONCOLOGY | ||||||
| 10/20/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $76.96 | General |
| Category: ONCOLOGY | ||||||
| 10/19/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $13,793.30 | General |
| Category: ONCOLOGY | ||||||
| 10/10/2024 | ABBVIE INC. | — | — | Cash or cash equivalent | $675.00 | Research |
| Study: Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC) (LIVIGNO-1) | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A phase 1b,2, multicenter, open-label study of S-531011 as monotherapy and in combination with an immune checkpoint inhibitor in participants with locally advanced or metastatic solid tumors | Merck Sharp & Dohme LLC | $1,360 | 1 |
| Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors | ABBVIE INC. | $1,350 | 1 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $1,212 | 2 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $1,164 | 2 |
| A Phase 1 First-in Human, Multi-Center, Open Label Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination with ABBV-181 in Subjects with Locally Advanced or Metastatic Solid Tumors | ABBVIE INC. | $825.00 | 1 |
| Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC) (LIVIGNO-1) | ABBVIE INC. | $675.00 | 1 |
| A Phase I/Ib study for the evaluation of SAR260301, administered orally in monotherapy in patients with advanced solid tumors or lymphomas, and in combination with vemurafenib in patients with unresec | GENZYME CORPORATION | $294.43 | 2 |
| RESEARCH RELATED PUBLICATION SUPPORT | Novartis Pharmaceuticals Corporation | $286.50 | 1 |
| MGD019 DART PROTEIN IN UNRESECTABLE METASTATIC CANCER | MacroGenics, Inc. | $117.00 | 1 |
| Safety Tolerability Pharmacokinetic Pharmacodynamic and Preliminary Efficacy Study of BMS 986205 Administered in Combination With Nivolumab in Advanced Cancers | E.R. Squibb & Sons, L.L.C. | $70.00 | 1 |
| A Phase I Study of BMS-986299 as Monotherapy and in Combination with Nivolumab and Ipilimumab in Participants with Advanced Solid Cancers | E.R. Squibb & Sons, L.L.C. | $65.00 | 1 |
| A Phase I Study of BMS-986301 Monotherapy and Combination Therapy With Nivolumab and Ipilimumab in Participants With Advanced Solid Cancers | E.R. Squibb & Sons, L.L.C. | $65.00 | 1 |
| A Phase I Study of BMS-986301 Monotherapy and Combination Therapy with Nivolumab and Ipilimumab in Participants with Advanced Solid Cancers | E.R. Squibb & Sons, L.L.C. | $65.00 | 1 |
| A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally Advanced or Metastatic Tumors | AbbVie Inc. | $20.68 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 119 | 211 | $49,636 | $19,133 |
| 2022 | 5 | 111 | 184 | $41,796 | $15,704 |
| 2021 | 4 | 122 | 189 | $45,064 | $17,902 |
| 2020 | 3 | 51 | 91 | $20,617 | $7,216 |
Total Patients
403
Total Services
675
Medicare Billing
$59,955
Procedure Codes
16
All Medicare Procedures & Services
16 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 46 | 79 | $20,224 | $8,443 | 41.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 24 | 78 | $14,040 | $4,738 | 33.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 30 | 30 | $10,860 | $4,159 | 38.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 19 | 24 | $4,512 | $1,793 | 39.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 41 | 77 | $19,712 | $8,308 | 42.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 24 | 24 | $8,688 | $3,123 | 35.9% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 20 | 45 | $8,100 | $2,435 | 30.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 13 | 17 | $3,196 | $1,300 | 40.7% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 13 | 21 | $2,100 | $538.43 | 25.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 42 | 66 | $16,896 | $7,597 | 45.0% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 31 | 31 | $11,280 | $4,596 | 40.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 29 | 41 | $7,708 | $2,981 | 38.7% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 20 | 51 | $9,180 | $2,728 | 29.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 22 | 61 | $11,392 | $3,902 | 34.2% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 15 | 15 | $5,430 | $2,049 | 37.7% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 14 | 15 | $3,795 | $1,265 | 33.3% |
About Dr. Jason Luke, M.D
Dr. Jason Luke, M.D is a Hematology & Oncology healthcare provider based in Pittsburgh, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/18/2008. The National Provider Identifier (NPI) number assigned to this provider is 1093989196.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jason Luke, M.D has received a total of $431,360 in payments from pharmaceutical and medical device companies, with $60,897 received in 2024. These payments were reported across 409 transactions from 38 companies. The most common payment nature is "Consulting Fee" ($302,339).
As a Medicare-enrolled provider, Luke has provided services to 403 Medicare beneficiaries, totaling 675 services with total Medicare billing of $59,955. Data is available for 4 years (2020–2023), covering 16 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Pittsburgh, PA
- Active Since 04/18/2008
- Last Updated 07/05/2023
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1093989196
Products in Payments
- KEYTRUDA (Biological) $55,013
- LIBTAYO (Biological) $29,096
- MEKINIST (Drug) $28,259
- BRAFTOVI (Drug) $6,538
- TAFINLAR (Drug) $6,226
- OPDIVO (Biological) $5,897
- Lenvima (Drug) $5,605
- IMFINZI (Drug) $5,211
- Bavencio (Biological) $4,696
- Epkinly (Drug) $2,685
- COSELA (Drug) $2,480
- TAFMAK_MEKINIST,TAFINLAR_ONCOLOGY (Drug) $1,550
- ZEJULA (Drug) $1,382
- Tepotinib $650.00
- LEUKINE (Drug) $620.00
- AFINITOR (Drug) $483.00
- MIW815 (Drug) $419.25
- Mavenclad (Biological) $353.52
- Non-Covered Product $318.65
- SAR260301 (Drug) $294.43
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Pittsburgh
Salman Fazal, M.d, M.D
Hematology & Oncology — Payments: $2.2M
Hematology & Oncology $2.2M
Cyrus Khan, M.d, M.D
Hematology & Oncology — Payments: $2.2M
Hematology & Oncology $2.2M
Dr. Alexander Barsouk, Md, MD
Hematology & Oncology — Payments: $905,454
Hematology & Oncology $905,454
Taofeek Owonikoko, M.d, M.D
Hematology & Oncology — Payments: $454,396
Hematology & Oncology $454,396
Dr. Hashem Younes, M.d, M.D
Hematology & Oncology — Payments: $451,665
Hematology & Oncology $451,665
Ahmad Tarhini, Md, MD
Hematology & Oncology — Payments: $290,751
Hematology & Oncology $290,751